The cannabinoid CB 1 receptor-mediated modulation of g-aminobutyric acid (GABA) release from inhibitory interneurons is important for the integrity of hippocampal-dependent spatial memory. Although adenosine A 1 receptors have a central role in fine-tuning excitatory transmission in the hippocampus, A 1 receptors localized in GABAergic cells do not directly influence GABA release. CB 1 and A 1 receptors are the main targets for the effects of two of the most heavily consumed psychoactive substances worldwide: D 9 -tetrahydrocannabinol (THC, a CB 1 receptor agonist) and caffeine (an adenosine receptor antagonist). We first tested the hypothesis that an A 1 -CB 1 interaction influences GABA and glutamate release in the hippocampus. We found that A 1 receptor activation attenuated the CB 1 -mediated inhibition of GABA and glutamate release and this interaction was manifested at the level of G-protein activation. Using in vivo and in vitro approaches, we then investigated the functional implications of the adenosine-cannabinoid interplay that may arise following chronic caffeine consumption. Chronic administration of caffeine in mice (intraperitoneally, 3 mg/kg/day, for 15 days, 412 h before trials) led to an A 1 -mediated enhancement of the CB 1 -dependent acute disruptive effects of THC on a short-term spatial memory task, despite inducing a reduction in cortical and hippocampal CB 1 receptor number and an attenuation of CB 1 coupling with G protein. A 1 receptor levels were increased following chronic caffeine administration. This study shows that A 1 receptors exert a negative modulatory effect on CB 1 -mediated inhibition of GABA and glutamate release, and provides the first evidence of chronic caffeine-induced alterations on the cannabinoid system in the cortex and hippocampus, with functional implications in spatial memory.
INTRODUCTION
The fine tuning of neuronal activity to suit specific cognitive functions is a major task of endogenous neuromodulators, of which adenosine and the endocannabinoids are two important examples. Both modulators are released by neurons and activate G-protein-coupled receptors (GPCRs) that represent some of the most widely and densely expressed GPCRs in the brain (Dunwiddie and Masino, 2001; Herkenham et al, 1990 ).
In the hippocampus, the predominant adenosine and cannabinoid receptors are the A 1 and CB 1 receptors, respectively. Several forms of learning, memory, and other cognitive functions require the integrity of the hippocampal circuitry, in which A 1 and CB 1 receptors were shown to have important roles owing to their presynaptic regulation of neurotransmitter release (eg, Ohno and Watanabe, 1996; Wise et al, 2009) . Moreover, in the hippocampus, these receptors are the main targets for the cognitive effects of two of the most heavily consumed psychoactive substances worldwide: caffeine and D
9
-tetrahydrocannabinol (THC) (Barone and Roberts, 1996; Leggett, 2006) .
Caffeine is present in various dietary sources, such as coffee, tea, and soft drinks, and at moderate doses is an adenosine receptor antagonist with cognitive-enhancing properties (Fredholm et al, 1999; Ribeiro and Sebastião, 2010) . As customary in most coffee consumers, long-term intake of caffeine leads to the development of tolerance to some of its acute effects by mechanisms not yet fully understood, although most studies found an increased number of A 1 , but not A 2A receptors, in several brain areas (Jacobson et al, 1996) . Chronic caffeine intake has also been associated with increased behavioral effects of some drugs of abuse, for example, amphetamine and cocaine (Gasior et al, 2000; Justinova et al, 2009) . THC is the main psychoactive constituent of the cannabis plant, which is consumed recreationally or used for medicinal purposes; it mainly activates cannabinoid CB 1 receptors in the central nervous system to produce motor-and cognitive-disrupting effects (see Pertwee, 2008) .
Hippocampal CB 1 receptors are primarily found in presynaptic terminals of cholecystokinin (CCK)-expressing g-aminobutyric acidergic (GABAergic) interneurons from the CA1 and CA3 subfields (Hájos et al, 2000; Katona et al, 1999) . CCK-expressing GABAergic interneurons regulate the temporal coordination in the activity of principal cell assemblies, which is critical for the integrity of hippocampal-dependent memory (Freund and Katona, 2007) . Accodingly, it was recently shown that presynaptic CB 1 receptors at GABAergic, but not glutamatergic, neurons are required for THC-induced amnesia (Puighermanal et al, 2009) . In contrast, A 1 receptors mostly affect excitatory synaptic transmission (Dunwiddie and Fredholm, 1989; Sebastião et al, 1990) , having no direct influence upon GABAergic transmission in mature hippocampal neurons (Jeong et al, 2003; Lambert and Teyler, 1991; Li and Henry, 2000; Yoon and Rothman, 1991) or on GABA release from isolated nerve terminals (Cunha and Ribeiro, 2000) . However, A 1 receptors are present in hippocampal GABAergic interneurons (Ochiishi et al, 1999) , in which they control the actions of vasoactive intestinal peptide (CunhaReis et al, 2008) .
Both A 1 and CB 1 receptors regulate synaptic transmission through activation of G-protein a i/o -subunits (Straiker et al, 2002) , which inhibit adenylyl cyclase, block voltage-gated calcium channels (VGCCs), and activate inwardly rectifying potassium channels (Dunwiddie and Masino, 2001; Howlett, 2005) . In the cerebellum, A 1 receptors modulate the motor incoordination effects induced by acute administration of THC or CB 1 receptor agonist CP55,940 (Dar, 2000; Dar and Mustafa, 2002; DeSanty and Dar, 2001) . Furthermore, prolonged intracerebellar administration of a CB 1 or A 1 agonist induces cross-tolerance (DeSanty and Dar, 2001) , and similar observations were obtained in two subsequent studies (Kouznetsova et al, 2002; Selley et al, 2004) . A more recent study observed that CB 1 -mediated inhibition of excitatory synaptic transmission in the hippocampus is modulated by endogenous adenosine, through A 1 receptor activation (Hoffman et al, 2010 ; but see Serpa et al, 2009 ). These previous findings raised the hypothesis that a functional interaction between A 1 and CB 1 receptors in the hippocampus may have cognitive and pathophysiological implications, particularly for the effects of cannabis and caffeine consumption in humans.
This study initially focused upon the possibility that an A 1 -CB 1 interaction influences GABA and glutamate release. We found that A 1 receptor activation attenuated the CB 1 -mediated inhibition of GABA and glutamate release, and that this interaction is manifested at the level of Gprotein activation. We then evaluated the functional consequences of chronic caffeine administration on the memory deficits induced by acute THC administration. Caffeine (intraperitoneally, 3 mg/kg/day, for 15 days, 412 h before trials) increased A 1 receptor levels, and did not by itself cause measurable effects on spatial memory, but led to an A 1 -mediated exacerbation of the CB 1 -dependent acute effects of THC in a spatial memory task.
MATERIALS AND METHODS

Animals
Adult male 6-8 weeks old Wistar rats (Harlan Interfauna Iberica, Barcelona, Spain) and 12-16 weeks old C57Bl/6J mice (Harlan-Olac, Bicester, UK) were used. Animals were housed in a temperature-and humidity-regulated room with a 12 h dark/light cycle, and free access to food and water. Experiments were performed during the light phase. All experimentation followed the UK Animals (Scientific Procedures) Act, 1986, Portuguese and European Union law concerning animal care. C57Bl/6J mice were used in all experiments involving chronic caffeine administration for logistic advantages and because mice have been extensively used in behavioral studies where the systemic effects of cannabinoids on motor and cognitive function have been assessed 3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone monomethanesulfonate (WIN55, , and N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251) were from Tocris Bioscience. (RS)-4-amino-3-(4-chlorophenyl)butanoic acid (baclofen) was from Ascent Scientific (Bristol, UK). All other reagents were from Sigma. For in vitro experiments, non-water-soluble drugs were dissolved in dimethyl sulfoxide (DMSO), aliquoted, and stored at À20 1C. The amount of DMSO in solutions was normalized for all conditions in any given experiment, and always o0.02%.
Synaptosomal Preparation
For each experiment, hippocampal synaptosomes were prepared from two rats, or cortico-hippocampal synaptosomes from one mouse. Animals were decapitated under halothane anesthesia and synaptosomes were prepared as described previously (Assaife- Lopes et al, 2010) , with modifications. Briefly, tissue was dissected in a continuously oxygenated (95% O 2 , 5% CO 2 ) ice-cold artificial cerebrospinal fluid (aCSF) of the following composition (mM): NaCl 125, KCl 3, NaH 2 PO 4 1, NaHCO 3 25, CaCl 2 1.5, MgSO 4 1.2, glucose 10, pH 7.4. Samples were homogenized in ice-cold 0.32 M sucrose solution containing 1 mM EDTA and 10 mM HEPES, pH 7.4. The homogenate was then centrifuged at 3000 g for 10 min, and the supernatant obtained was centrifuged at 14 000 g for 12 min to obtain a stratified pellet, containing synaptosomes (McMahon et al, 1992; Phelan and Gordon-Weeks, 1997 ]glutamate experiments, the synaptosomal pellet was resuspended in aCSF, which did not contain AOAA, and synaptosomes were incubated for 5 min, at 371C with 10 mCi/ml [ 3 H]glutamate. Synaptosomes were then layered over GF/C filters (Milipore, MA, USA) on an eight-chamber superfusion (0.8 ml/min) apparatus (Raiteri et al, 1974) . This constant and rapid flow rate washes out endogenously released substances, thus ensuring drug effect specificity (see Raiteri and Raiteri, 2000) . After a 30-min washout period, samples were continuously collected for 36 min, in 2-min fractions. Synaptosomes were stimulated during 2 min with 15 mM K + (isomolar substitution of Na + with K + ) at the 6th (S 1 ) and 24th (S 2 ) minutes of collection time. CB 1 agonists were added to the superfusion medium from the 18th minute onward, to measure effects on S 2 . The CB 1 antagonist, AM251, or A 1 and GABA B receptor ligands were added from the 15th minute of the washout period onward, that is, present during S 1 and S 2 in order to assess their ability to modify the effect of WIN55,212-2 (applied before S 2 ). Each condition was tested in duplicate, as commonly accepted in this paradigm (eg, Cunha and Ribeiro, 2000) . Under similar conditions, the percentage of GABA and glutamate in the K + -evoked outflow is 490% of the total tritium in the sample (Cunha et al, 1997; Lopes et al, 2002) . Fractional [ 3 H]neurotransmitter release was expressed as the percentage of total radioactivity present in the synaptosomes at each time point (fractional release). The amount of tritium released after each pulse of K + (S 1 or S 2 ) was calculated by integration of the peak area. Effects were calculated by normalizing the S 2 /S 1 values of corresponding controls from the same batch of synaptosomes to 0% effect. For example, the effect of WIN55,212-2 (added before S 2 ), in the presence of CPA (during S 1 and S 2 ), was calculated using the S 2 /S 1 of CPA alone (during S 1 and S 2 ) as a control, which was obtained from the same experiment and batch of synaptosomes.
Binding Assays
Rat hippocampal or mouse cortico-hippocampal membranes were prepared as described previously (eg, Cunha et al, 1999) , with modifications. Tissue was homogenized in ice-cold 0.32 M sucrose solution containing 2 mM EGTA, 1 mM DTT, and 50 mM Tris, pH 7.6. The homogenate was centrifuged at 1000 g for 10 min, and the supernatant obtained was centrifuged at 14 000 g for 12 min. The pellets were resuspended in assay buffer and incubated with 4 U/ml ADA for 30 min at 37 1C, followed by centrifugation at 14 000 g for 12 min and resuspension in assay buffer. Assay buffer composition, in mM, for radioligand binding assays was: Tris 50, MgCl 2 2, pH 7.4 and for [
35 S]GTPgS binding assays it was: Tris 50, MgCl 2 5, NaCl 100, EGTA 0.2, pH 7.4. Protein content was determined by the Bradford method (Bradford, 1976 (Breivogel et al, 1998) . Specific binding was calculated by subtracting nonspecific binding obtained by incubation with 10 mM GTPgS. The effect of co-application of CPA or baclofen with CB 1 agonists was calculated by subtracting the increase in [ 35 S]GTPgS induced by CPA or baclofen alone. The reactions were stopped by vacuum filtration through GF/C filters, followed by washing with ice-cold buffer.
In Vivo Drug Administration
Mice were randomly assigned to various groups and habituated to the handling during 5 days before testing began. For chronic treatment with caffeine, animals received caffeine (3 mg/kg/day), or vehicle (saline: 0.9% NaCl), 412 h before trials, for at least 15 days before experimental days, and throughout the course of behavioral testing, in order to avoid withdrawal effects. Total caffeine exposure was for 22-24 days, and euthanization occurred 24 h after last injection. The half-life of caffeine for doses lower than 10 mg/kg ranges from 0.7 to 1.2 h in the rat and mouse (Fredholm et al, 1999) ; therefore, the estimated concentrations of caffeine present in plasma or brain during behavioral testing were negligible. For acute administration, animals received a single dose of vehicle (8% Tween-80 in saline), THC (5 mg/kg), AM251 (3 mg/kg), DPCPX (1 mg/kg), or WIN55,212-2 (1 mg/kg). THC was prepared in Tween-80 as described previously (Pertwee et al, 1992) ; AM251, DPCPX, and WIN55,212-2 were suspended in the vehicle and carefully sonicated. All drugs were given by intraperitoneal injection in a volume of 2 ml/kg weight. The concentration of Tween-80 used was previously shown not to affect motor activity in mice (Castro et al, 1995) .
Water Maze Experiments (Trials to Criterion Task)
We performed two separate sets of water maze experiments, in which mice were randomly assigned to four experimental groups of seven to eight subjects (total of 57 animals). The protocol is a version of the Morris water maze test that is sensitive to hippocampal-dependent short-term spatial learning (Chen et al, 2000; Daumas et al, 2007) . To form a stable representation of the environment, mice were first trained to quickly find a hidden platform at a fixed platform location for 5 consecutive days. Subjects then performed several tasks, each consisting of a new platform position. Each animal was given a maximum of eight trials per day, to perform the task until reaching a performance criterion of p7 s average latency on three consecutive trials. A 15 min intertrial interval was applied, during which animals were allowed to dry under a ceramic heat lamp. Once the criterion was reached, trials stopped and a new task began on the following testing day. Animals first performed 4-5 training tasks in order to learn to optimize their search strategies, and then the effects of acute drug administration were tested in separate tasks, as described in the Results section.
A black infrared-translucent Perspex tank (1 m in diameter) of water (temperature, 22 ± 1 1C) was placed over an infrared lightbox (Tracksys, Nottingham, UK) in a room with various visible external cues. A transparent platform was B0.5 cm below the water surface and its position varied between several possible locations, on two concentric circles, according to the original protocol. An infraredsensitive automated tracking system (Noldus Ethovision 7.0, Noldus Information Technology, Wageningen, the Netherlands) monitored all performances.
Statistical Analysis
Statistical significance was tested using paired Student's t-test, one-or two-way analysis of variance (ANOVA), followed by Dunnett's or Tukey's post hoc tests, as indicated. The two-way ANOVA and post hoc tests were performed using the Predictive Analytics Software 18.0 (SPSS, an IBM Company, Chicago, IL). GraphPad Prism 5.0 (GraphPad Prism Software, San Diego, CA, USA) was used for all other statistical tests and nonlinear regression curve fitting. Differences in parameters between binding curves were tested using extra sum-of-squares F test. In control conditions, pooling data from all experiments performed, the average basal release of [ 3 H]GABA from rat hippocampal synaptosomes was 0.76 ± 0.02% (n ¼ 31, average of first 6 min of collection; Figure 1a ) of the total tritium retained by synaptosomes at the same time points. Depolarization of the hippocampal synaptosomes with K + (15 mM) for 2 min induced a threefold increase in the [ 3 H]GABA release with an average peak of 2.5 ± 0.1% during S 1 , and 2.3 ± 0.1% (n ¼ 31; Figure 1a) To induce a CB 1 receptor-dependent effect on [ 3 H]GABA release, we used the potent cannabinoid receptor agonist WIN55,212-2, which has been previously shown to inhibit evoked [ 3 H]GABA release from hippocampal synaptosomes through a CB 1 -specific mechanism, having a maximum CB 1 -selective effect at 1 mM (Köfalvi et al, 2007) . Application of 1 mM WIN55,212-2 6 min before S 2 caused a decrease of basal [ (Figure 1c ). As WIN55,212-2 is known to directly block Ntype VGCCs at concentrations above 1 mM (Németh et al, 2008; Shen and Thayer, 1998) , we tested the specificity of its effect in our preparation using the CB 1 antagonist AM251, as well as WIN55,212-3, an enantiomer of WIN55,212-2 that does not activate the CB 1 receptor, but maintains the Ca 2 + channel-blocking properties (Shen and Thayer, 1998) . AM251 (1 mM) fully blocked the effect of 1 mM, but not of 10 mM of WIN55,212-2 ( Figure 1c ). Higher concentrations of AM251 were not used to avoid loss of selectivity (see Köfalvi, 2007 Köfalvi, , 2008 . The enantiomer had no significant effect applied at 1 mM, but it inhibited evoked [ 3 H]GABA release by 22.4 ± 1.4% at 10 mM (n ¼ 5, po0.05; Figure 1c ), which indicates that the effect of 1 mM WIN55,212-2 upon [ 3 H]GABA release is CB 1 receptor dependent. It is worth noting that the effect of 10 mM WIN55,212-2 was larger than the effect of 10 mM WIN55,212-3, which indicates that the effect of 10 mM WIN55,212-2 still encompasses a CB 1 receptor-dependent component. The partial CB 1 agonist THC (1 mM) inhibited K + -evoked [ 3 H]GABA release by 8.9±0.9% (n ¼ 8, po0.05; Figure 1c ).
RESULTS
Consistent with previous observations (Cunha and Ribeiro, 2000) , adenosine A 1 receptor activation with the selective agonist CPA (100 nM) before S 2 did not affect K + -evoked [ 3 H]GABA release (2.7±3% of control S 2 /S 1 , n ¼ 3, p40.05, data not shown). To evaluate the influence of A 1 receptors on the CB 1 -mediated inhibition of GABA release, we tested the effect of WIN55,212-2 (applied before S 2 ) in the presence of CPA (100 nM, applied throughout the experiment, S 1 + S 2 ). Under these conditions, the effect of WIN55,212-2 at 1 mM (n ¼ 10) and at 10 mM (n ¼ 7) was significantly attenuated (po0.01 and o0.05, respectively; Figure 2a ). The average effect of 1 mM WIN55,212-2 was 18±3% (n ¼ 10) and CPA attenuated this effect to 12±2% (po0.01, n ¼ 10), which represents a 33±13% decrease in the average effect of WIN55,212-2 alone. To test if the attenuation of the effect of 10 mM WIN55,212-2 caused by CPA occurred through a Ca 2 + channel-dependent mechanism and not involving CB 1 receptors, we performed the experiments using WIN55,212-3. Application of WIN55, 212-3 (10 mM, S 2 ) by itself inhibited [ 3 H]GABA release by 22 ± 2%, whereas in the presence of CPA (100 nM), its effect was unaltered (22 ± 2%, n ¼ 3; Figure 2a ). This indicates that the CPA-induced attenuation of the effect of WIN55, 212-2 was exerted at the CB 1 receptor-dependent component, but not upon the Ca 2 + channel-dependent mechanisms, affected by high micromolar concentrations of WIN55,212-2. The blockade of A 1 receptors with the antagonist DPCPX (50 nM) did not, on its own, alter the effects of 1 and 10 mM WIN55,212-2, but it fully prevented the CPA-induced attenuation (p40.05, n ¼ 7, paired Student's t-test; Figure 2b ).
The signaling pathways of CB 1 , A 1 , and GABA B are known to converge when co-expressed in cerebellar neurons (Selley et al, 2004) . Furthermore, both CB 1 and GABA B receptors are present in inhibitory interneurons (Katona et al, 1999; Sloviter et al, 1999) , couple to the same Ga i/o -subunits (Straiker et al, 2002) , and exhibit reciprocal inhibition (Cinar et al, 2008) in hippocampal neurons. We therefore evaluated whether the A 1 receptor-dependent attenuation of the effect of WIN55,212-2 was mimicked by the activation of GABA B receptors. As shown in Figure 2c , the effect of WIN55,212-2 (1 mM) was unchanged (p40.05, n ¼ 5, paired Student's t-test) by the presence of the GABA B receptor agonist baclofen (10 mM). Altogether, these results indicate that the cannabinoid CB 1 receptors in GABAergic nerve terminals are under the modulatory influence of adenosine A 1 receptors, but not GABA B receptors.
Despite the predominant influence of CB 1 receptors in hippocampal circuitry being exerted through the inhibition of GABA release, CB 1 receptors at glutamatergic presynaptic nerve terminals (Katona et al, 2006; Kawamura et al, 2006) also inhibit the K + -evoked release of glutamate (eg, Cannizzaro et al, 2006; D'Amico et al, 2004; Köfalvi et al, 2007) . Importantly, the regulation of excitatory synaptic transmission is the most relevant role of the hippocampal A 1 receptors (Dunwiddie and Fredholm, 1989; Sebastião et al, 1990) . To investigate whether A 1 receptors also -tetrahydrocannabinol (THC) (1 mM), as well as of a WIN enantiomer that is inactive at the CB 1 receptor, WIN55,212-3 (WIN-3; 1-10 mM), is also shown. WIN significantly inhibited [ 3 H]GABA release at all concentrations (po0.01), except for the lowest concentration tested (0.01 mM, p40.05); THC (1 mM) also significantly inhibited [ 3 H]GABA release (po0.01). Note that WIN-3 was devoid of the effect at 1 mM (p40.05), but not at 10 mM (po0.01), and that AM251 antagonized the effect of 1 mM, but not of 10 mM WIN, indicating that WIN is CB 1 receptor selective at 1 mM, but not at 10 mM. Each point represents the mean±SEM of 4-10 independent experiments performed in duplicate, except (n ¼ 2) for 0.01 and 3 mM WIN, and 1 mM WIN-3. The S 2 /S 1 values from corresponding controls were taken as 0% within each experiment. P-values were obtained by a one-way analysis of variance (ANOVA) test with Dunnett post hoc, compared with control (0%). SKF, Cd 2 + , and AM251 were applied 15 min before the start of sample collection and were continuously perfused throughout the experiment, being therefore present during S 1 and S 2 (S 1 + S 2 ); WIN, WIN-3, and THC were added before S 2 (see Materials methods for further details).
regulate the CB 1 -dependent effects upon glutamate release, the influence of A 1 receptor activation on the CB 1 -mediated inhibition of K + -evoked [ 3 H]glutamate release was also tested. The absence of a tonic activation of A 1 receptors by endogenous adenosine was first assessed by using A 1 receptor blocker DPCPX. As Figure 3a shows, WIN55,212-2 (1 mM) inhibited the release of [ As shown in Figure 3b , the inhibitory effect of 1 mM WIN55,212-2 upon glutamate release (19±2%) was significantly attenuated to 7 ± 2% (n ¼ 5, po0.01; Figure 3b ) in the presence of CPA. We then evaluated whether the A 1 receptor-mediated inhibition of glutamate release is also under the modulatory control of CB 1 receptors, by comparing the effect of CPA (before S 2 ) in the absence and in the presence of 1 mM WIN55,212-2. CPA (100 nM) inhibited [ 3 H]glutamate release by 12±4%, and this effect was not modified in the presence of 1 mM WIN55,212-2 (13 ± 2%, n ¼ 4, p40.05; Figure 3b ). These findings further indicate that A 1 receptors negatively modulate the CB 1 -mediated effects in the hippocampus and support recent evidence that CB 1 -mediated inhibition of excitatory synaptic transmission in the hippocampus is modulated by A 1 receptor activation (Hoffman et al, 2010) . ]GABA release from rat hippocampal synaptosomes. (a) Effects of WIN55,212-2 (WIN, 1 and 10 mM) and of its CB 1 receptor-inactive enantiomer, WIN55,212-3 (WIN, 3, 10 mM), in the absence or in the presence of the selective A 1 receptor agonist, CPA (100 nM), as indicated below each column. Note that CPA significantly attenuated the effect of 1 and 10 mM WIN (**po0.01, *po0.05, respectively, compared with the effect of WIN in the absence of CPA, in the same experiments), whereas the effect of WIN55,212-3 (WIN-3) (10 mM) was unaffected by CPA (p40.05). (b) WIN (1 and 10 mM) was tested in the absence or in the presence of selective A 1 receptor antagonist, DPCPX (50 nM), alone and in combination with CPA (100 nM). (c) WIN (1 mM) was tested in the absence or in the presence of the selective GABA B receptor agonist, baclofen (10 mM), as indicated below the column. Note that in the presence of DPCPX, CPA did not attenuate the inhibitory effect of WIN (p40.05), and that baclofen did not modify the effect of WIN (1 mM) (p40.05). Bars represent the mean ± standard error of mean (SEM) of 3-10 individual experiments performed in duplicate. The S 2 /S 1 values from controls were taken as 0% within each experiment. P-values were obtained by paired Student's t-test, compared with corresponding controls within the same batch of synaptosomes. WIN and WIN-3 were added before S 2 , whereas the other drugs were applied 15 min (CPA or baclofen) or 30 min (DPCPX) before the start of sample collection, being therefore present during S 1 and S 2 (see Materials and methods for further details). Figure 4a and Table 1 ). CPA (100 nM) by itself induced a 150 ± 12% net increase from basal [
35 S]GTPgS binding (n ¼ 4). Coapplication of WIN55,212-2 (0.1 nM-10 mM) with 100 nM CPA (Figure 4a ) significantly decreased the E max of WIN55,212-2 to 204 ± 10% (po0.001, n ¼ 4; Table 1 ), but not the EC 50 (E177 nM; Table 1 ). This indicates a functional interaction between colocalized CB 1 and A 1 receptors in hippocampal membranes, which impacts on the ability of CB 1 receptors to activate Ga i/o proteins. Similarly, the co-application of THC (0.1 nM-1 mM) with 100 nM CPA (Figure 4b ) significantly decreased the E max of THC from 163±8% (when applied alone) to 129±13% (n ¼ 4, po0.05; 
Chronic Caffeine Administration Increases Acute THC-Induced Spatial Memory Deficits in Mice
The evidence that A 1 receptor activation attenuates CB 1 receptor signaling raised the hypothesis that this A 1 -CB 1 interplay has a functional impact upon hippocampaldependent memory. Chronic caffeine consumption is known to induce an increase in adenosine A 1 , but not A 2A receptors (reviewed by Jacobson et al, 1996) . Acute systemic THC administration induces CB 1 -dependent deficits in working memory (Wise et al, 2009 ). Therefore, we used a hippocampal-dependent, short-term spatial memory testing protocol (Chen et al, 2000 ; see Materials and methods) to study the effects of chronic caffeine administration on the memory deficits induced by an acute systemic 35 S]GTPgS, and varying concentrations of (a) WIN55,212-2 (0.1 nM-10 mM) or (b) THC (0.1 nM-1 mM), alone (J) or in combination with 100 nM CPA ('), or 100 mM baclofen (~). E max and log EC 50 values are shown in Table 1 . Data represent mean percentage of basal stimulation±SEM of n ¼ 7 (J) and n ¼ 4 (',~), performed in duplicate. Non-visible error bars are within symbols. Figure 3 . a po0.05, compared with appropriate control, calculated using the extra sum-ofsquares F test.
THC injection in mice. Two separate sets of experiments were performed, in which caffeine (3 mg/kg/day), or vehicle, was administered 412 h before trials, and for at least 15 days before the first test with THC.
During the training phase, all subjects learned to perform efficiently at all test parameters, in both sets of experiments (see Figures 5a-c and 6a-c) . The number of trials, the total latency, and total pathlength needed to reach the criterion decreased progressively from task to task reaching a plateau in the last training task. A repeated measures two-way ANOVA on these parameters revealed a significant overall learning effect. For 'pathlength' (representative parameter of memory performance), significance values were: F(4, 100) ¼ 10.2, po0.0001 ( Figure 5c ); and F(3, 72) ¼ 13.5, po0.0001 (Figure 6c ). The average swim speed (control parameter for motor activity) was constant throughout the training tasks ( In both sets of experiments, there were no differences between groups and no 'group Â task' interaction in any parameter during the training period (p40.05 for all parameters). Thus, chronic caffeine administration by itself did not affect memory performance or motor activity.
For the first set of experiments, the effect of THC (5 mg/kg), or vehicle, given at task 6 (30 min before first trial), as well as the modification of this effect by AM251 (3 mg/kg), given at task 7 (15 min before THC, or vehicle), are displayed in Figure 5a -d. After completion of task 6, each subject rested for 1 day to allow for the metabolic clearance of THC.
There was a significant effect of THC on 'trials to criterion' (F(1, 25) ¼ 4.24, p ¼ 0.05), 'latency' (F(1, 25) ¼ 6.98, p ¼ 0.01), and 'pathlength' (F(1, 25) ¼ 7.18, p ¼ 0.01), but no significant effect on 'average speed' (F(1, 25)o0.001, p ¼ 0.98). There were no effects of chronic caffeine treatment on all parameters, but a marginally significant 'chronic caffeine Â THC' interaction on 'pathlength' (F(1,25) ¼ 3.11, p ¼ 0.09). Although acute THC injection (vs vehicle) did not induce significant effects in the control (vehicle-treated) group at any parameter, the effect of THC was exacerbated in the chronic caffeine group, on 'latency' (p ¼ 0.03, Tukey's post hoc; Figure 5b ) and 'pathlength' (p ¼ 0.02, Tukey's post hoc; Figure 5c ).
When mice received AM251 pretreatment, there were no significant effects of any treatment group on all parameters, indicating that the effects of THC were dependent on the activation of CB 1 receptors. These results show that chronic caffeine exacerbates the CB 1 -dependent actions of THC in a short-term spatial memory task.
For the second set of experiments, the effect of THC (5 mg/kg), or vehicle, given at task 5 (30 min before first trial), the modification of this effect by DPCPX (1 mg/kg), given at task 7 (15 min before THC, or vehicle), as well as the effect of WIN55,212-2 (1 mg/kg), or vehicle, given at task 8 (30 min before first trial), are displayed in Figure 6a d. After completion of each test task, subjects rested for one -tetrahydrocannabinol (THC)-induced short-term spatial memory deficits in mice. Caffeine was given daily (3 mg/kg, 412 h before trials), for 15 days before testing the effect of THC (see Methods). (a-d) Mice familiarized with the escape strategies during the first 5 tasks (training) and all groups showed improved performance in (a) the number of trials to reach criterion, (b) the escape latency, (c) swim pathlength, whereas (d) average swim speed remained constant. THC (5 mg/kg), or vehicle, was then tested in the absence (task 6) and in the presence (task 7) of AM251 (3 mg/kg). Subjects rested for 1 day off drug after task 6, to allow full metabolization of THC. For clarity of comparison between groups, symbols were nudged at tasks 6 and 7. Note that chronic caffeine exacerbated the spatial memory deficits induced by acute THC, and this effect of THC was fully prevented by previous administration of AM251. All data represent mean±standard error of mean (SEM) of n ¼ 7-8. *po0.05, two-way analysis of variance, followed by Tukey's post hoc test (see text for more details).
day off-drug to allow for metabolic clearance of THC. Task 6 was a control test in which no acute drug was given, to measure whether performance levels returned to baseline values 48 h after acute THC administration.
Consistent with the first set of experiments, there was a significant effect of THC on 'trials to criterion' (F(1, 24) ¼ 6.34, p ¼ 0.02), 'latency' (F(1, 24) ¼ 8.16, p ¼ 0.01), and 'pathlength' (F(1, 24) ¼ 9.19, p ¼ 0.01), but no significant effect on 'average speed' (F(1, 24) ¼ 2.09, p ¼ 0.16). On 'pathlength' there was also a significant effect of chronic caffeine treatment (F(1, 24) ¼ 4.82, p ¼ 0.04), and a marginally significant 'chronic caffeine Â THC' interaction (F(1, 24) ¼ 3.29, p ¼ 0.08). Although acute THC injection (vs vehicle) did not induce significant effects in the control (vehicle-treated) group at any parameter, the effect of THC was exacerbated in the chronic caffeine group, on 'latency' (p ¼ 0.02, Tukey's post hoc; Figure 6b ) and 'pathlength' (p ¼ 0.01, Tukey's post hoc; Figure 6c ). There were also significant differences between THC on the chronic caffeine group vs THC in the vehicle group on 'pathlength' (p ¼ 0.04), and between THC on the chronic caffeine group vs the vehicle control group on 'trials to criterion' (p ¼ 0.05), 'latency' (p ¼ 0.01), and 'pathlength' (p ¼ 0.006).
When mice were tested 48 h after the last THC injection, there were no significant effects of any treatment group on all parameters, indicating that the effects of THC were not prevailing after this period. Importantly, when mice received a pretreatment of DPCPX, there were also no significant effects of any treatment group on all parameters, indicating that the effects of THC were reversed by the blockade of A 1 receptors.
Finally, there was a significant effect of WIN55,212-2 on 'trials to criterion' (F(1, 24) ¼ 7.64, p ¼ 0.01), 'latency' (F(1, 24) ¼ 7.50, p ¼ 0.01), and 'pathlength' (F(1, 24) ¼ 7.74, p ¼ 0.01), but no significant effect on 'average speed' (F(1, 24) ¼ 4.03, p ¼ 0.06). The acute injection of WIN55, 212-2 (vs vehicle) did not induce significant effects in the control (vehicle-treated) group at any parameter, but its effects were exacerbated in the chronic caffeine group, on 'latency' (p ¼ 0.03, Tukey's post hoc; Figure 6b ) and 'pathlength' (p ¼ 0.03, Tukey's post hoc; Figure 6c ). There were also significant differences between WIN55,212-2 on the chronic caffeine group vs the vehicle control group on 'latency' (p ¼ 0.03) and 'pathlength' (p ¼ 0.03). The lower effect of WIN55,212-2, compared with that of THC, could be owing to pharmacokinetic differences, as the penetration of WIN55,212-2 in the brain following intraperitoneal injection is much lower than that of THC (Petitet et al, 1999) . Higher doses of WIN55,212-2 were not used to avoid nonspecific effects . These findings show a significant chronic caffeine-induced, and A 1 receptor-mediated, exacerbation of the CB 1 -dependent effects on short-term spatial memory.
Chronic Caffeine and A 1 Receptor Number
To quantify the influence of chronic caffeine administration upon A 1 receptor number and affinity in cortico-hippo- -tetrahydrocannabinol (THC) and WIN55,212-2 on mice tested in a short-term spatial memory task. Caffeine was given daily (3 mg/kg, 412 h before trials), for 15 days before testing the effect of THC (see Methods). (a-d) Mice familiarized with the escape strategies during the first 4 tasks (training) and all groups showed improved performance in (a) the number of trials to reach criterion, (b) the escape latency, and (c) swim pathlength, whereas (d) average swim speed remained constant. THC (5 mg/kg), or vehicle, was tested in the absence (task 5) and in the presence (task 7) of DPCPX (1 mg/kg). A control (CTR) test in the absence of acute drugs was performed at task 6 to measure whether performance levels returned to baseline values. Subjects rested for one day off drug after each test task, to allow full metabolization of THC. The effect of WIN55,212-2 (WIN, 1 mg/kg), or vehicle, was tested at task 8. For clarity of comparison between groups, symbols were nudged in tasks 5-8. Note that chronic caffeine exacerbated the spatial memory deficits induced by acute THC and WIN. The effect of THC was prevented by the previous administration of DPCPX. All data represent mean±standard error of mean (SEM) of n ¼ 7. *po0.05, **po0.01, two-way analysis of variance, followed by Tukey's post hoc tests (see text for more details). campal membranes, [ (Figure 7) . In vehicle-treated mice, the total number of specific binding sites obtained by nonlinear regression analysis (B max ) was 848±44 fmol/mg of protein, whereas the equilibrium dissociation constant (K D ) was 1.20 ± 0.21 nM. In the chronic caffeine group, the B max was increased to 980±50 fmol/mg of protein (po0.05, n ¼ 6, vs vehicle group), but K D (1.31 ± 0.23 nM) was not significantly (p40.05) affected. Thus, animals under chronic caffeine had B16% higher density of A 1 receptor without changes in affinity.
Chronic Caffeine and CB 1 Receptor Signaling in Mouse Cortico-Hippocampal Tissue
We first tested the consistency of our in vitro results between rats and mice by testing the effect of CPA (100 nM) on the WIN55,212-2-mediated inhibition of K + -evoked [ 3 H]GABA release from cortico-hippocampal synaptosomes prepared from untreated mice (Figure 8 ). Consistent to previous observations in rats, the effect of 1 mM WIN55,212-2 alone was 19 ± 1%, and it was significantly attenuated to 9±1% in the presence of CPA (po0.01, n ¼ 4, paired Student's t-test; Figure 8 ). We then analyzed the influence of chronic caffeine administration upon the CB 1 receptormediated inhibition of K + -evoked [ ]GABA release by 17 ± 1%, whereas in the chronic caffeine group, the effect of WIN55,212-2 was significantly reduced to 11±2% (po0.05, n ¼ 4, paired Student's t-test; Figure 8 ).
As Figure 9 and Table 2 show, in cortico-hippocampal membranes of vehicle-treated mice, WIN55,212-2 stimulated [
35 S]GTPgS binding (% of basal) with an EC 50 E989 nM and E max ¼ 321 ± 11% (n ¼ 5; Figure 9a ), whereas THC had an EC 50 E41 nM and E max ¼ 167±11% (n ¼ 4; Figure 9c ). Chronic caffeine administration did not affect the EC 50 of WIN55,212-2 or THC, but it significantly reduced the E max of WIN55,212-2 to 269 ± 8%, and of THC to 135 ± 8% (po0.05, n ¼ 4-5, extra sum-of-squares F test; Figure 9a and c). As observed in rats (Figure 4a) , the co-application of 100 nM CPA in control mice significantly decreased the E max of WIN55,212-2 (254 ± 13%, po0.05, n ¼ 5, extra sum-of-squares F test; Figure 9b and Table 2 ), but not the EC 50 . This reduction in WIN55,212-2-stimulated [ 35 S]GTPgS binding, caused by CPA in membranes from control animals, was of similar magnitude as the decrease observed in the chronic caffeine-treated group in the absence of CPA (Table 2 ). In the chronic caffeine group, CPA did not induce a further decrease in the efficacy of WIN55,212-2 to stimulate G-protein activation (E max ¼ 252 ± 8%; Figure 9a and b and (Figure 9a and b) or THC (Figure 9c ) is represented as 100% in the ordinates, which corresponds to (fmol/mg protein): Figure 9a and bF143 ± 10 (J, n ¼ 5), 154 ± 15 (~, n ¼ 5), 324 ± 13 (n, n ¼ 5), and 327 ± 25 (., n ¼ 5); Figure 9cF53±9 (J, n ¼ 4) and 67±10 (~, n ¼ 4). CPA (100 nM), by itself, enhanced [
35 S]GTPgS binding by 122 ± 9% (over twofold net increase from basal binding) in membranes prepared from vehicle-treated subjects, and by 111 ± 7% in the chronic caffeine group (p40.05, n ¼ 5, Student's t-test, data not shown); hence, the ability of A 1 receptors to activate G proteins is unaltered in chronic caffeine-treated mice. Accordingly, there were no statistically significant differences in the bottom of the nonlinear regression binding curves between chronic caffeine-and vehicle-treated animals, in the presence of CPA (p40.05, n ¼ 5, extra sum-of-squares F test; Figure 9b ).
Chronic Caffeine and CB 1 Receptor Number
The effects of chronic caffeine administration upon CB 1 signaling in vitro suggested that CB 1 receptor number and/or affinity are decreased in these mice. We then directly analyzed the effect of chronic caffeine administration in CB 1 receptor number and affinity by performing [ 
DISCUSSION
This study shows that adenosine A 1 receptors located in GABAergic and glutamatergic nerve terminals of the hippocampus exert a negative modulatory effect on the cannabinoid CB 1 receptor-mediated inhibition of GABA and glutamate release. CB 1 -mediated G-protein activation is also impaired by A 1 receptor activation. In addition, chronic administration of caffeine leads to an A 1 receptormediated enhancement of the CB 1 -dependent effects of THC upon short-term spatial memory, despite a reduction in CB 1 receptor number and signaling. This provides first evidence for chronic caffeine-induced alterations in cannabinoid actions in the cortex and hippocampus.
The CB 1 -A 1 receptor cross-talk might occur at the G-protein level, as A 1 receptor activation with CPA reduced the efficacy of CB 1 receptor agonists to stimulate [
35 S]GTPgS binding in the hippocampus. This is in accordance with a previous observation that simultaneous application of CB 1 and A 1 agonists produces less than additive stimulation of [ 35 S]GTPgS binding in cerebellar membranes (Selley et al, 2004) . Similarly to the A 1 receptors, GABA B receptors couple to Ga i/o proteins and are expressed in the same interneuron populations as CB 1 receptors (Neu et al, 2007; Sloviter et al, 1999 ]GABA release with a maximum specific effect at 1 mM, in agreement with previous studies Köfalvi et al, 2007) . There are clear differences in the magnitude of the reported effects of WIN55,212-2 in studies using different methodologies. For example, we and others (Köfalvi et al, 2007) observed that 1 mM WIN55,212-2 induces 15-20% inhibition of K + -evoked [ 3 H]GABA release from rat hippocampal synaptosomes, whereas several reports show that the same concentration of WIN55,212-2, by activating presynaptic CB 1 receptors, inhibits GABAergic inhibitory postsynaptic currents (IPSCs) in rat hippocampal slices by B50% (eg, Hájos et al, 2000; Hoffman and Lupica, 2000; Wilson and Nicoll, 2001 ). These differences are likely owing to a combination of factors. The main reason possibly lies in the fact that [ 3 H]GABA release assays provide a quantitative measurement of the amount of GABA released from the whole population of GABAergic nerve terminals at the hippocampus, whereas patch-clamp techniques provide a quantification of endogenous GABA release by measuring the post-synaptic responses of a single hippocampal pyramidal neuron. In addition, differences are likely owing to the type of stimulus used (electrical vs high K + ), the time and length of WIN55,212-2 application, and to an amplifying effect of multiple afferents upon IPSC measurements. The effect of 1 mM WIN55,212-2 on the release of [ 3 H]GABA from rat hippocampal slices (Katona et al, 1999) is also larger than in synaptosomes. Again, a longer exposure time (6 vs 18 min) to WIN55,212-2 and/or the amplification by intrinsic circuits in the slices is a likely explanation for these differences.
The CB 1 receptor-mediated modulation of GABA release from hippocampal CCK-positive interneurons, which express large quantities of CB 1 receptors, is a critical mechanism for spatial and episodic memory, as these interneurons regulate the temporal coordination of principal cell assemblies (Hájos et al, 2000; Robbe and Buzsáki, 2009; Robbe et al, 2006) . However, the CCK-expressing interneuron populations mostly receive input from glutamatergic neurons (see Freund and Buzsáki, 1996; Freund and Katona, 2007) , which also express CB 1 (Katona et al, 2006; Kawamura et al, 2006) and A 1 (Ochiishi et al, 1999) receptors. We found that A 1 receptor activation also attenuates CB 1 receptor-mediated inhibition of glutamate release from hippocampal synaptosomes. It was recently reported that endogenous adenosine, by activating A 1 receptors, regulates CB 1 -mediated inhibition of glutamatergic synaptic transmission (Hoffman et al, 2010 ; but see Serpa et al, 2009 WIN55,212-2 did not attenuate the inhibitory action of CPA upon glutamate release, suggesting that the modulatory action of A 1 receptors upon CB 1 receptors is not reciprocal.
The relevance of the GABAergic circuitry for the CB 1 receptor-mediated influences upon memory function became firmly established after the demonstration that intraperitoneal THC administration disrupts hippocampaldependent memory through the activation of CB 1 receptors (Wise et al, 2009) in GABAergic, but not glutamatergic, neurons (Puighermanal et al, 2009) . We now show that chronic administration of a moderate dose of caffeine leads to increased levels of A 1 receptors in the cortico-hippocampal membranes, and to an A 1 receptor-mediated increase of the disruptive effects of acute THC in a hippocampal-dependent short-term spatial memory task. This finding points toward a significant functional relevance of the cross-talk between A 1 and CB 1 receptors in the hippocampus. Interestingly, the motor impairments induced by THC are enhanced by acute activation of A 1 receptors (Dar, 2000) . In contrast, acute administration of caffeine antagonizes THC-induced changes in corticohippocampal EEG wave recordings (Consroe et al, 1976) . Several studies show that chronic exposure to adenosine receptor antagonists causes similar actions to acute agonist exposure (see Jacobson et al, 1996; Von Lubitz et al, 1993) , whereas acute administration of caffeine is expected to have opposite effects to acute agonist exposure. The timing of caffeine administration and the presence of caffeine in the blood during testing must also be taken into account when comparing data from different studies. The behavioral tests now reported were performed in the absence of relevant plasma concentrations of caffeine (412 h after caffeine injection), which was given 2 h after the last behavioral trial, to prevent effects on memory consolidation (Angelucci et al, 2002) . It is therefore not surprising that acute caffeine administration prevents THC-induced effects (Consroe et al, 1976) , whereas chronic caffeine exposure exacerbates the memory disruption induced by CB 1 receptor agonists (present work). In a recent study, chronic administration of a high dose of caffeine (210 mg/kg/day) in rats was shown to potentiate CB 1 -dependent effects at striatal GABAergic, but not glutamatergic, synapses (Rossi et al, 2009) . However, it is difficult to draw a comparison with this study, given the differences in the experimental approach, namely the dose of caffeine used, which is not adenosine receptor-selective and is more than about 70 times higher than the equivalent daily human intake. Exposure to high doses of caffeine (B100 mg/kg/day) leads to altered brain levels of several receptors (Shi et al, 1993 (Shi et al, , 1994 , inhibit phosphodiesterases, and may even block GABA A receptors, among others (see Daly and Fredholm, 1998) .
The conclusion that A 1 receptors are involved in the chronic caffeine-induced exacerbation of the effects of THC presently reported is reinforced by the finding that A 1 receptor blockade with DPCPX fully prevented the effects of THC in the chronic caffeine group. DPCPX was administered at a dose that occupies A 1 receptors (Baumgold et al, 1992; Hooper et al, 1996) while not affecting motor activity (present work; Von Lubitz et al, 1993) . In addition, DPCPX by itself had no effects in the absence of THC, which suggests that A 1 receptors do not directly influence shortterm spatial memory. Furthermore, acute application of DPCPX did not influence the action of THC in vehicletreated animals, which further supports previous evidence (see above) that chronic and acute blockade of A 1 receptors have different functional consequences. The effects of DPCPX also exclude the involvement of A 2A receptors, which are known to modulate the actions of CB 1 receptors in the striatum (Carriba et al, 2007; Tebano et al, 2009) . A 1 and A 2A receptors have similar affinities for caffeine (Fredholm et al, 1994 ), yet the expression of A 2A receptors in the hippocampus and cortex is much lower than that of A 1 receptors (reviewed by Ribeiro et al, 2002) . Furthermore, chronic caffeine exposure does not alter the expression of A 2A receptors (Jacobson et al, 1996) .
The increase in A 1 receptor expression caused by moderate doses of chronically administered caffeine results from prevention of tonic adenosine-mediated receptor downregulation (see Fredholm et al, 1999) . The dose of caffeine we have administered to mice is equivalent to the estimated US average human daily caffeine consumption (Barone and Roberts, 1996) and, in addition to the expected increase in A 1 receptor levels, it also caused a decrease of cortical and hippocampal CB 1 receptors. Accordingly, in chronic caffeine-treated mice there was a reduction in the CB 1 receptor-mediated inhibition of GABA release and stimulation of G-protein activation. As tonic activation of A 1 receptors was prevented through elimination of endogenous adenosine by vertical superfusion in the [ 3 H]GABA release assays, and by ADA in the [
35 S]GTPgS binding assays, it is unlikely that chronic caffeine-induced A 1 receptor upregulation could be responsible for reduction of CB 1 -dependent actions in the in vitro assays. Most probably, chronic caffeine intake, by inducing an imbalance in adenosinergic signaling, disturbs the A 1 -CB 1 cross-talk, which reflects in CB 1 receptor downregulation. Independently of the exact mechanisms involved, it is clear that CB 1 receptors are affected after chronic caffeine exposure.
Given that chronic caffeine decreases CB 1 and increases A 1 receptor levels, and that activation of A 1 receptors inhibited the CB 1 -mediated actions in the in vitro assays, it was somewhat surprising that the memory impairment caused by the CB 1 receptor agonists was exacerbated by chronic caffeine intake. It is therefore evident that changes observed in vitro do not necessarily reflect, in a linear way, the effects upon the integrated hippocampal circuitry in vivo. An imbalance in GABAergic transmission resulting from the chronic caffeine-induced alterations of A 1 and CB 1 levels may have occurred, leading to some adaptive changes in the pyramidal cells and/or in the parvalbumin-expressing (PV) GABAergic neurons, which do not express CB 1 receptors (Katona et al, 1999) . Interestingly, the blockade of GABAergic transmission was shown to reverse the cognitive effects of acute THC in vivo (Varvel et al, 2005) . A critical imbalance in the temporal coordination of pyramidal cell firing could have become evident when THC was administered, if there was an enhanced sensitivity to the fast spiking activity of PV cells; hence, leading to increased inhibition of pyramidal cell firing.
In summary, this work highlights two relevant factors influencing cannabinoid CB 1 signaling in the hippocampus: the activity of A 1 receptors and the chronic consumption of caffeine. This A 1 -CB 1 receptor interaction therefore points toward the possibility that the pathophysiological or therapeutically relevant actions operated by CB 1 receptors can be significantly affected by interference with A 1 receptor activity, as is the case of chronic caffeine intake.
